nach oben

Pathology & Oncology Research

Erschienen in:

18.01.2017 | Original Article

Antitumor Efficacy of SLPI Promoter-Controlled Expression of Artificial microRNA Targeting EGFR in a Squamous Cell Carcinoma Cell Line

verfasst von: Jia Chen, Shoude Zhang, Yi Lin, Beibei Yang, Jiang Cao

Erschienen in: Pathology & Oncology Research | Ausgabe 4/2017

Einloggen, um Zugang zu erhalten

Abstract

The purpose of this study was to develop a recombinant adenovirus with secretory leukoprotease inhibitor (SLPI) promoter-controlled expression for gene therapy of squamous cell carcinoma (SCC). An artificial microRNA targeting epidermal growth factor receptor (EGFR) was designed, and used to construct a replication-defective recombinant adenovirus with SLPI promoter-controlled expression. The silencing efficiency of this vector (Ad-SLPI-EGFRamiR) was detected in Hep-2 cells. Western blotting showed that the expression of 170 kD EGFR was significantly reduced in Hep-2 cells 72 h after infection with Ad-SLPI-EGFRamiR. At a multiplicity of infection (MOI) of 200 pfu/cell, proliferation of Hep-2 cells was highly inhibited by Ad-SLPI-EGFRamiR (inhibition rate: ~70%). The apoptosis rate of Hep-2 cells at 72 h after infection with Ad-SLPI-EGFRamiR at a MOI 35 pfu/cell was 32.8%. The adenovirus constructed was able to specifically inhibit the growth of SCC cells in vitro.

Alam M, Ratner D (2001) Cutaneous squamous-cell carcinoma. N Engl J Med 344:975–983CrossRefPubMed

Yan W, Wistuba II, Emmert-Buck MR, Erickson HS (2011) Squamous cell carcinoma – similarities and differences among anatomical sites. Am J Cancer Res 1:275–300CrossRefPubMed

Pfister DG, Ang KK, Brizel DM et al (2011) Head and neck cancers. J Natl Compr Cancer Netw 9:596–650CrossRef

Olsen KD (2010) Reexamining the treatment of advanced laryngeal cancer. Head Neck 32:1–7PubMed

Zhang S, Chen J, Jiang H, MA H, Yang B (2012) Anti-epidermal growth factor receptor therapy for advanced head and neck squamous cell carcinoma: a meta-analysis. Eur J Clin Pharmacol 68:561–569CrossRefPubMed

Bonner JA, Harari PM, Giralt J et al (2006) Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354:567–578CrossRefPubMed

Vermorken JB, Mesia R, Rivera F et al (2008) Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 359:1116–1127CrossRefPubMed

Moon C, Chae YK, Lee J (2010) Targeting epidermal growth factor receptor in head and neck cancer: lessons learned from cetuximab. Exp Biol Med (Maywood) 235:907–920CrossRef

Wheeler DL, Dunn EF, Harari PM (2010) Understanding resistance to EGFR inhibitors-impact on future treatment strategies. Nat Rev Clin Oncol 7:493–507CrossRefPubMedPubMedCentral

10.

Young NR, Liu J, Pierce C et al (2013) Molecular phenotype predicts sensitivity of squamous cell carcinoma of the head and neck to epidermal growth factor receptor inhibition. Mol Oncol 7:359–368CrossRefPubMed

11.

Sharafinski ME, Ferris RL, Ferrone S, Grandis JR (2010) Epidermal growth factor receptor targeted therapy of squamous cell carcinoma of the head and neck. Head Neck 32:1412–1421CrossRefPubMedPubMedCentral

12.

Normanno N, De Luca A, Bianco C et al (2006) Epidermal growth factor receptor (EGFR) signaling in cancer. Gene 366:2–16CrossRefPubMed

13.

Rapisarda A, Melillo G (2012) Role of the VEGF/VEGFR axis in cancer biology and therapy. Adv Cancer Res 114:237–267CrossRefPubMed

14.

Herbst RS (2004) Review of epidermal growth factor receptor biology. Int J Radiat Oncol Biol Phys 59:21–26CrossRefPubMed

15.

Uribe P, Gonzalez S (2011) Epidermal growth factor receptor (EGFR) and squamous cell carcinoma of the skin: molecular bases for EGFR-targeted therapy. Pathol Res Pract 207:337–342CrossRefPubMed

16.

Mitsudomi T, Yatabe Y (2010) Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer. FEBS J 277:301–308CrossRefPubMed

17.

Rothenberg SM, Engelman JA, Le S, Riese DJ 2nd, Haber DA, Settleman J (2008) Modeling oncogene addiction using RNA interference. Proc Natl Acad Sci U S A 105:12480–12484CrossRefPubMedPubMedCentral

18.

Wang Z, Rao DD, Senzer N, Nemunaitis J (2011) RNA interference and cancer therapy. Pharm Res 28:2983–2995CrossRefPubMed

19.

Chang K, Elledge SJ, Hannon GJ (2006) Lessons from nature: microRNA-based shRNA libraries. Nat Methods 3:707–714CrossRefPubMed

20.

Rein DT, Breidenbach M, Curiel DT (2006) Current developments in adenovirus- based cancer gene therapy. Future Oncol 2:137–143CrossRefPubMedPubMedCentral

21.

Dorer DE, Nettelbeck DM (2009) Targeting cancer by transcriptional control in cancer gene therapy and viral oncolysis. Adv Drug Deliv Rev 61:554–571CrossRefPubMed

22.

Chen J, Yang B, Zhang S et al (2012) Antitumor potential of SLPI promoter controlled recombinant caspase-3 expression in laryngeal carcinoma. Cancer Gene Ther 19:328–335CrossRefPubMed

23.

Hynes NE, Lane HA (2005) ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 5:341–354CrossRefPubMed

24.

Nukiwa T, Suzuki T, Fukuhara T, Kikuchi T (2008) Secretory leukocyte peptidase inhibitor and lung cancer. Cancer Sci 99:849–855CrossRefPubMed

25.

Maemondo M, Saijo Y, Narumi K et al (2004) Gene therapy with secretory leukoprotease inhibitor promoter-controlled replication-competent adenovirus for non-small cell lung cancer. Cancer Res 64:4611–4620CrossRefPubMed

26.

Rein DT, Breidenbach M, Kirby TO et al (2005) A fiber-modified, secretory leukoprotease inhibitor promoter-based conditionally replicating adenovirus for treatment of ovarian cancer. Clin Cancer Res 11:1327–1335PubMed

27.

Khare R, Chen CY, Weaver EA, Barry MA (2011) Advances and future challenges in adenoviral vector pharmacology and targeting. Curr Gene Ther 11:241–258CrossRefPubMedPubMedCentral

28.

Thaci B, Ulasov IV, Wainwright DA, Lesniak MS (2011) The challenge for gene therapy: innate immune response to adenoviruses. Oncotarget 2:113–121CrossRefPubMedPubMedCentral

29.

Douglas JT, Rogers BE, Rosenfeld ME, Michael SI, Feng M, Curiel DT (1996) Targeted gene delivery by tropism-modified adenoviral vectors. Nat Biotechnol 14:1574–1578CrossRefPubMed

30.

Mizuguchi H, Hayakawa T (2004) Targeted adenovirus vectors. Hum Gene Ther 15:1034–1044CrossRefPubMed

31.

Wu H, Han T, Belousova N et al (2005) Identification of sites in adenovirus hexon for foreign peptide incorporation. J Virol 79:3382–3390CrossRefPubMedPubMedCentral

32.

Wickham TJ, Segal DM, Roelvink PW et al (1996) Targeted adenovirus gene transfer to endothelial and smooth muscle cells by using bispecific antibodies. J Virol 70:6831–6838PubMedPubMedCentral

33.

Xia D, Henry LJ, Gerard RD, Deisenhofer J (1994) Crystal structure of the receptor-binding domain of adenovirus type 5 fiber protein at 1.7 a resolution. Structure 2:1259–1270CrossRefPubMed

34.

Leemans CR, Braakhuis BJ, Brakenhoff RH (2011) The molecular biology of head and neck cancer. Nat Rev Cancer 11:9–22CrossRefPubMed

35.

Widakowich C, de Castro G Jr, de Azambuja E, Dinh P, Awada A (2007) Review: side effects of approved molecular targeted therapies in solid cancers. Oncologist 12:1443–1455CrossRefPubMed

Titel: Antitumor Efficacy of SLPI Promoter-Controlled Expression of Artificial microRNA Targeting EGFR in a Squamous Cell Carcinoma Cell Line
verfasst von: Jia Chen
Shoude Zhang
Yi Lin
Beibei Yang
Jiang Cao
Publikationsdatum: 18.01.2017
Verlag: Springer Netherlands
Erschienen in: Pathology & Oncology Research / Ausgabe 4/2017
Print ISSN: 1219-4956
Elektronische ISSN: 1532-2807
DOI: https://doi.org/10.1007/s12253-016-0160-8

Neu im Fachgebiet Onkologie

19.04.2024 | EAU 2024 | Kongressbericht | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Antitumor Efficacy of SLPI Promoter-Controlled Expression of Artificial microRNA Targeting EGFR in a Squamous Cell Carcinoma Cell Line

Abstract

Neu im Fachgebiet Onkologie

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2017

Vasculogenic Mimicry in Clinically Non-functioning Pituitary Adenomas: a Histologic Study

Marked Differences of Haplotype Tagging SNP Distribution, Linkage, and Haplotype Profile of APOA5 Gene in Roma Population Samples

miR-10b, miR-26a, miR-146a And miR-153 Expression in Triple Negative Vs Non Triple Negative Breast Cancer: Potential Biomarkers

Anastomosing Hemangioma of the Ovary: A Clinicopathological Study of Six Cases with Stromal Luteinization

Unusual Signal Patterns of Break-apart FISH Probes Used in the Diagnosis of Soft Tissue Sarcomas

Comparison of Core Needle Biopsy and Excision Specimens for the Accurate Evaluation of Breast Cancer Molecular Markers: a Report of 1003 Cases

Neu im Fachgebiet Onkologie

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Update Onkologie